Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
PRE 14A
Preliminary proxy
28 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22 Feb 24
8-K
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
10 Aug 23
8-K
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
22 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Athira Pharma Reports First Quarter 2023 Financial Results
11 May 23
ARS
2022 FY
Annual report to shareholders
5 Apr 23
DEFA14A
Additional proxy soliciting materials
5 Apr 23
DEF 14A
Definitive proxy
5 Apr 23
S-8
Registration of securities for employees
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
23 Mar 23
8-K
Entry into a Material Definitive Agreement
6 Jan 23
424B5
Prospectus supplement for primary offering
6 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
10 Nov 22
8-K
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
17 Oct 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
15 Aug 22
8-K
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
22 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
24 May 22
DEFA14A
Additional proxy soliciting materials
17 May 22
DEFA14A
Additional proxy soliciting materials
16 May 22
DFAN14A
Additional proxy materials by non-management
16 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Athira Pharma Reports First Quarter 2022 Financial Results
12 May 22
DFAN14A
Additional proxy materials by non-management
12 May 22
DEFA14A
Additional proxy soliciting materials
11 May 22
DEFA14A
Additional proxy soliciting materials
9 May 22
DEFA14A
Additional proxy soliciting materials
5 May 22
Latest ownership filings
4
Martin Javier San
16 Apr 24
3
Martin Javier San
16 Apr 24
4
Mark James Litton
16 Feb 24
4
Mark Worthington
16 Feb 24
4
KEVIN CHURCH
16 Feb 24
4
Andrew Gengos
16 Feb 24
4
Rachel Lenington
16 Feb 24
4/A
Rachel Lenington
16 Feb 24
4/A
Mark James Litton
16 Feb 24
4/A
Mark Worthington
16 Feb 24
4/A
Andrew Gengos
16 Feb 24
4/A
KEVIN CHURCH
16 Feb 24
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
4
HANS MOEBIUS
8 Jan 24
4
Andrew Gengos
8 Jan 24
4
Mark James Litton
8 Jan 24
4
Mark Worthington
8 Jan 24
4
KEVIN CHURCH
8 Jan 24
4
Rachel Lenington
8 Jan 24
4
JOSEPH EDELMAN
29 Dec 23
SC 13D/A
PERCEPTIVE ADVISORS LLC
29 Dec 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
Andrew Gengos
9 Jun 23
4
Andrew Gengos
6 Jun 23
4
HANS MOEBIUS
6 Jun 23
4
Kelly A Romano
22 May 23
4
JAMES A JOHNSON
22 May 23
4
Barbara Kosacz
22 May 23
4
JOSEPH EDELMAN
22 May 23
4
Michael A. Panzara
22 May 23
4
JOHN M FLUKE JR
22 May 23
4
GRANT PICKERING
22 May 23
4
Andrew Gengos
22 May 23
3
Andrew Gengos
22 May 23
SC 13G
KAYNE RICHARD A
20 Apr 23
4
GRANT PICKERING
31 Mar 23
4
JAMES A JOHNSON
30 Mar 23
4
KEVIN CHURCH
27 Mar 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23